EGIS 11004Alternative Names: S 36550
Latest Information Update: 16 Aug 2007
At a glance
- Originator Egis Pharmaceuticals
- Developer Egis Pharmaceuticals; Servier
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Anxiety disorders